ClinicalTrials.gg
CompletedNCT04623775Updated Jun 18, 2026Results posted

A Study of Relatlimab Plus Nivolumab in Combination With Chemotherapy vs. Nivolumab in Combination With Chemotherapy as First Line Treatment for Participants With Stage IV or Recurrent Non-small Cell Lung Cancer (NSCLC)

A Phase 2 interventional study of Nivolumab and Relatlimab in Non-small Cell Lung Cancer, Recurrent Non-small Cell Lung Cancer and Metastatic Non-small Cell Lung Cancer, sponsored by Bristol-Myers Squibb. Completed at 125 sites in 19 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-18.

Sponsored by Bristol-Myers Squibb · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
468
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 131 studies in Carcinoma, Non-Small-Cell Lung by Bristol-Myers Squibb — 21 open to participants now, 35 under way, 10 of them phase 3. Carcinoma, Non-Small-Cell Lung · Bristol-Myers Squibb.

Enrollment
23rd of 107
468 · median 169
Started
2021
with 9 others
Phase 2
32 of 131
3 open now
Registered
81st of 131
by date

Among the 131 studies in Carcinoma, Non-Small-Cell Lung by Bristol-Myers Squibb, this one is the 23rd largest by enrollment of the 107 interventional ones that give a count, is one of 10 that started in 2021, is one of 32 in phase 2, and was the 81st registered.

Carcinoma, Non-Small-Cell Lung

7,632 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,839 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

21 of the 131 studies in Carcinoma, Non-Small-Cell Lung by Bristol-Myers Squibb are open now, in 12 countries. Recruiting first, the newest first:

16 more — sign in →

By country, each count listing its studies:

All 21 open studies →

Who these studies take

Of the 1,324 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 224 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 131 studies in Carcinoma, Non-Small-Cell Lung by Bristol-Myers Squibb, or all of them as a file.
02

Study summary

The purpose of this study is to assess the safety profile of relatlimab plus nivolumab in combination with platinum doublet chemotherapy (PDCT) and to determine if nivolumab plus relatlimab in combination with PDCT improves overall response rate (ORR) when compared to nivolumab plus PDCT in participants with previously untreated Stage IV or recurrent non-small cell lung cancer (NSCLC).

03

Conditions studied

  • Non-small Cell Lung Cancer
  • Recurrent Non-small Cell Lung Cancer
  • Metastatic Non-small Cell Lung Cancer

Keywords

  • Stage IV Non-small Cell Lunch Cancer
  • Recurrent Non-small Cell Lung Cancer
  • Metastatic Non-small Cell Lung Cancer
  • Relatlimab
  • Nivolumab
  • Chemotherapy
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • confirmed non-small cell lung cancer (NSCLC) of squamous (SQ) or non-squamous (NSQ) histology with Stage IV A/B (as defined by the 8th International Association for the Study of Lung Cancer Classification) or recurrent disease following multi-modal therapy for locally advanced disease.
  • (ECOG) performance status (PS) of less than or equal to 1 at screening and confirmed prior to randomization.
  • by computed tomography (CT) or magnetic resonance resources (MRI) per response evaluation criteria in solid tumor version 1.1 ( 1.1) criteria.
  • No prior systemic anti-cancer treatment (including epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) inhibitors) given as primary therapy for advanced or metastatic disease.

Exclusion criteria

Exclusion Criteria

  • Participants with EGFR, ALK, ROS-1, or known B-rapidly accelerated fibrosarcoma proto-oncogene (BRAF V600E) mutations that are sensitive to available targeted therapy.
  • Untreated .
  • (carcinomatous meningitis).
  • Concurrent requiring treatment or history of prior malignancy active within 2 years prior to randomization (ie, participants with a history of prior malignancy are eligible if treatment was completed at least 2 years before randomization and the participant has no evidence of disease).
  • Prior treatment with an anti-programmed cell death protein 1 (), anti-programmed death-ligand 1 (PD-L1), anti-programmed death-ligand 2 (PD-L2), or anti-cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) antibody, or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways.
  • Other protocol-defined Inclusion/Exclusion criteria apply.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
468 participants (actual)

Study arms

  • Experimental
    Part 1: Arm A (Nivolumab + Relatlimab Dose 1 + Platinum Doublet Chemotherapy (PDCT))

    Biological: Nivolumab · Biological: Relatlimab · Drug: Carboplatin · Drug: Cisplatin · Drug: Paclitaxel · Drug: Nab-Paclitaxel · Drug: Pemetrexed

  • Experimental
    Part 1: Arm B (Nivolumab + Relatlimab Dose 2 + PDCT))

    Biological: Nivolumab · Biological: Relatlimab · Drug: Carboplatin · Drug: Cisplatin · Drug: Paclitaxel · Drug: Nab-Paclitaxel · Drug: Pemetrexed

  • Experimental
    Part 2: Arm C (Nivolumab + Relatlimab Dose 2 + PDCT)

    Biological: Nivolumab · Biological: Relatlimab · Drug: Carboplatin · Drug: Cisplatin · Drug: Paclitaxel · Drug: Pemetrexed

  • Active comparator
    Part 2: Arm D (Nivolumab + PDCT)

    Biological: Nivolumab · Drug: Carboplatin · Drug: Cisplatin · Drug: Paclitaxel · Drug: Pemetrexed

Interventions

  • BiologicalNivolumab

    Specified dose on specified days

  • BiologicalRelatlimab

    Specified dose on specified days

  • Specified dose on specified days. Participant will receive only two of the listed chemotherapies (carboplatin, cisplatin, paclitaxel, nab-paclitaxel) along with immunotherapy.

  • Specified dose on specified days. Participant will receive only two of the listed chemotherapies (carboplatin, cisplatin, paclitaxel, nab-paclitaxel) along with immunotherapy.

  • Specified dose on specified days. Participant will receive only two of the listed chemotherapies (carboplatin, cisplatin, paclitaxel, nab-paclitaxel) along with immunotherapy.

  • Specified dose on specified days. Participant will receive only two of the listed chemotherapies (carboplatin, cisplatin, paclitaxel, nab-paclitaxel) along with immunotherapy.

  • Specified dose on specified days. Participant will receive only two of the listed chemotherapies (carboplatin, cisplatin, paclitaxel, nab-paclitaxel) along with immunotherapy.

06

What researchers measure

Primary outcomes

  1. TRAEs Leading to Discontinuation Within 12 Weeks of First Dose in Part 1

    Percentage of participants with treatment related adverse events (TRAEs) leading to discontinuation within 12 weeks of first dose. AE is defined as any new untoward medical occurrence or worsenig of a preexising medical condition in a clinical investigation participant administered study treatment and that does not necessarily have a causal relationship with this treatment. Grading will be determined for severity according to the NCI CTCAE v5.0.

    Time frame: from first dose to 12 weeks after first dose

  2. ORR Per RECISTS v1.1 by BICR in Part 2

    Objective Response Rate (ORR) per RECIST v1.1 by BICR is defined as the number of participants in the randomized population who achieve a best overall response (BOR) of confirmed complete response (CR) or confirmed partial response (PR) based on BICR assessments (using RECIST v1.1) divided by the number of participants in the population. BOR is defined as the best response, as determined by the BICR, recorded between the date of randomization and the date of first objectively documented progression per RECIST v1.1 or the date of subsequent therapy, whichever occurs first.

    Time frame: Approximately 14.8 Months

Secondary outcomes

  1. TRAEs Leading to Discontinuation in Part 1

    Number of participants with treatment related adverse events (TRAEs) leading to discontinuation based on grade. AE is defined as any new untoward medical occurrence or worsenig of a preexising medical condition in a clinical investigation participant administered study treatment and that does not necessarily have a causal relationship with this treatment. Grading will be determined for severity according to the NCI CTCAE v5.0

    Time frame: From first dose to 30 days post last dose of study therapy (Approximately 32.8 Months)

  2. Number of Participants With a Treatment Related AEs in Part 1

    Number of participants with a treatment related AE in part 1. AE is defined as any new untoward medical occurrence or worsenig of a preexising medical condition in a clinical investigation participant administered study treatment and that does not necessarily have a causal relationship with this treatment. Grading will be determined for severity according to the NCI CTCAE v5.0

    Time frame: From first dose to 30 days post last dose of study therapy (Approximately 32.8 Months)

  3. Number of Participants With Treatment Releted SAEs in Part 1

    A serious adverse event (SAE) is defined as any untoward medical occurrence that at any dose, results in death, is life-threatening, requires inpatient hospitalization or causes prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, or is an important medical event (defined as a medical event(s) that may not be immediately life-threatening or result in death or hospitalization but, based upon appropriate medical and scientific judgment, may jeopardize the participant or may require intervention \[e.g., medical, surgical\] to prevent one of the other serious outcomes listed in the definition). Grading will be determined for severity according to the NCI CTCAE v5.0.

    Time frame: From first dose to 30 days post last dose of study therapy (Approximately 32.8 Months)

  4. Number of Participants With Treatment Releted Select AEs in Part 1

    AE is defined as any new untoward medical occurrence or worsenig of a preexising medical condition in a clinical investigation participant administered study treatment and that does not necessarily have a causal relationship with this treatment. Select Adverse Events (AEs) will be determined for severity according to the NCI CTCAE v5.0.

    Time frame: From first dose to 30 days post last dose of study therapy (Approximately 32.8 Months)

  5. ORR by PD-L1 Expression Per RECISTS v1.1 by BICR in Part 2

    Objective Response Rate (ORR) per RECIST v1.1 by BICR is defined as the number of participants in the randomized population who achieve a best overall response (BOR) of confirmed complete response (CR) or confirmed partial response (PR) based on BICR assessments (using RECIST v1.1) divided by the number of participants in the population. BOR is defined as the best response, as determined by the BICR, recorded between the date of randomization and the date of first objectively documented progression per RECIST v1.1 or the date of subsequent therapy, whichever occurs first.

    Time frame: Approximately 14.8 Months

  6. DoR Per RECISTS v1.1 by BICR in Part 2

    Duration of Response (DOR) will be assessed by BICR. It is defined as the time between the date of first documented response (CR or PR) that is subsequently confirmed, to the date of the first objectively documented tumor progression as determined by the BICR (per RECIST v1.1), or death due to any cause, whichever occurs first.

    Time frame: Approximately up to 13.7 months

  7. Number of Participants With a AE in Part 2

    Number of participants with an adverse event (AE). AE is defined as any new untoward medical occurrence or worsenig of a preexising medical condition in a clinical investigation participant administered study treatment and that does not necessarily have a causal relationship with this treatment. Grading will be determined for severity according to the NCI CTCAE v5.0.

    Time frame: From first dose to 30 days post last dose of study therapy (Approximately 14.8 Months)

  8. Number of Participants With a Treatment Related AEs in Part 2

    AE is defined as any new untoward medical occurrence or worsenig of a preexising medical condition in a clinical investigation participant administered study treatment and that does not necessarily have a causal relationship with this treatment. Grading will be determined for severity according to the NCI CTCAE v5.0.

    Time frame: From first dose to 30 days post last dose of study therapy (Approximately 14.8 Months)

  9. Number of Participants With a Treatment Related SAEs in Part 2

    SAE is defined as a life-threatening (defined as an event in which the participant was at risk of death at the time of the event; it does not refer to an event which hypothetically might have caused death if it were more severe). SAEs can also result in death. The AE requires inpatient hospitalization or causes prolongation of existing hospitalization. Results in persistent or significant disability/incapacity. Is a congenital anomaly/birth defect. Is an important medical event (defined as a medical event(s) that may not be immediately lifethreatening or result in death or hospitalization but, based upon appropriate medical and scientific judgment, may jeopardize the participant or may require intervention \[e.g., medical, surgical\] to prevent one of the other serious outcomes listed in the definition above.) Grading will be determined for severity according to the NCI CTCAE v5.0.

    Time frame: From first dose to 30 days post last dose of study therapy (Approximately 14.8 Months)

  10. Number of Participants With Endocrine Immune-mediated Adverse Events in Part 2

    IMAEs are AEs consistent with an immune-mediated mechanism or immune-mediated component for which non-inflammatory etiologies (eg, infection or tumor progression) have been ruled out. IMAEs can include events with an alternate etiology which were exacerbated by the induction of autoimmunity. Grading will be determined for severity according to the NCI CTCAE v5.0.

    Time frame: From first dose to 30 days post last dose of study therapy (Approximately 14.8 Months)

  11. ORR by LAG-3 Expression Per RECISTS v1.1 by BICR in Part 2

    Objective Response Rate (ORR) per RECIST v1.1 by BICR is defined as the number of participants in the randomized population who achieve a best overall response (BOR) of confirmed complete response (CR) or confirmed partial response (PR) based on BICR assessments (using RECIST v1.1) divided by the number of participants in the population. BOR is defined as the best response, as determined by the BICR, recorded between the date of randomization and the date of first objectively documented progression per RECIST v1.1 or the date of subsequent therapy, whichever occurs first.

    Time frame: On Going

  12. ORR by FG-L1 Expression Per RECISTS v1.1 by BICR in Part 2

    Objective Response Rate (ORR) per RECIST v1.1 by BICR is defined as the number of participants in the randomized population who achieve a best overall response (BOR) of confirmed complete response (CR) or confirmed partial response (PR) based on BICR assessments (using RECIST v1.1) divided by the number of participants in the population. BOR is defined as the best response, as determined by the BICR, recorded between the date of randomization and the date of first objectively documented progression per RECIST v1.1 or the date of subsequent therapy, whichever occurs first.

    Time frame: Ongoing

  13. PFS Per RECISTS v1.1 by BICR in Part 2

    Progression Free Survival is defined as the time between the date of randomization and the first date of documented progression, based on BICR assessments (per RECIST v1.1), or death due to any cause, whichever occurs first.

    Time frame: Ongoing

  14. PFS by PD-L1 Expression Per RECISTS v1.1 by BICR in Part 2

    Progression Free Survival is defined as the time between the date of randomization and the first date of documented progression, based on BICR assessments (per RECIST v1.1), or death due to any cause, whichever occurs first.

    Time frame: Ongoing

  15. PFS by LAG-3 Expression Per RECISTS v1.1 by BICR in Part 2

    Progression Free Survival is defined as the time between the date of randomization and the first date of documented progression, based on BICR assessments (per RECIST v1.1), or death due to any cause, whichever occurs first.

    Time frame: Ongoing

  16. PFS by FG-L1 Expression Per RECISTS v1.1 by BICR in Part 2

    Progression Free Survival is defined as the time between the date of randomization and the first date of documented progression, based on BICR assessments (per RECIST v1.1), or death due to any cause, whichever occurs first.

    Time frame: Ongoing

  17. Number of Participants With Treatment Releted Select AEs in Part 2

    AE is defined as any new untoward medical occurrence or worsenig of a preexising medical condition in a clinical investigation participant administered study treatment and that does not necessarily have a causal relationship with this treatment. Select Adverse Events (AEs) will be determined for severity according to the NCI CTCAE v5.0.

    Time frame: Ongoing

07

Results

Posted Mar 18, 2025

Participant flow

Randomization
Participant flow — Randomization
MilestonePart 1: Treatment APart 1: Treatment BPart 2: Treatment CPart 2: Treatment D
Started7980158151
Completed7779158149
Not completed2102
Withdrew: No longer meets study criteria2100
Withdrew: Withdrew consent0001
Withdrew: Other reasons0001
Treatment Period
Participant flow — Treatment Period
MilestonePart 1: Treatment APart 1: Treatment BPart 2: Treatment CPart 2: Treatment D
Started7779158149
Completed9126160
Not completed68679789
Withdrew: Participant withdrew consent4012
Withdrew: Death3142
Withdrew: Lost to follow-up0200
Withdrew: Poor/non compliance0010
Withdrew: Participant no longer meets study criteria0100
Withdrew: Administrative reasons by sponsor3200
Withdrew: Other reasons2011
Withdrew: Disease progression40356363
Withdrew: Study drug toxicity12151312
Withdrew: Ae unrelated to study drug49129
Withdrew: Participant request to discontinue treatment0220

Outcome measures

PrimaryTRAEs Leading to Discontinuation Within 12 Weeks of First Dose in Part 1

Percentage of participants with treatment related adverse events (TRAEs) leading to discontinuation within 12 weeks of first dose. AE is defined as any new untoward medical occurrence or worsenig of a preexising medical condition in a clinical investigation participant administered study treatment and that does not necessarily have a causal relationship with this treatment. Grading will be determined for severity according to the NCI CTCAE v5.0.

Time frame:
from first dose to 12 weeks after first dose
Reported as:
Number · Percentage of Participants
TRAEs Leading to Discontinuation Within 12 Weeks of First Dose in Part 1
Percentage of ParticipantsPart 1: Treatment APart 1: Treatment B
TRAEs Leading to Discontinuation Within 12 Weeks of First Dose in Part 15.6 (1.6 to 13.8)12.1 (5.4 to 22.5)
Statistical analysis
  • Part 1: Treatment A vs Part 1: Treatment B · Risk difference (rd): -6.5 · 95% CI -16.0 to 3.0
PrimaryORR Per RECISTS v1.1 by BICR in Part 2

Objective Response Rate (ORR) per RECIST v1.1 by BICR is defined as the number of participants in the randomized population who achieve a best overall response (BOR) of confirmed complete response (CR) or confirmed partial response (PR) based on BICR assessments (using RECIST v1.1) divided by the number of participants in the population. BOR is defined as the best response, as determined by the BICR, recorded between the date of randomization and the date of first objectively documented progression per RECIST v1.1 or the date of subsequent therapy, whichever occurs first.

Time frame:
Approximately 14.8 Months
Reported as:
Number · Percentage of Participants
ORR Per RECISTS v1.1 by BICR in Part 2
Percentage of ParticipantsPart 2: Treatment CPart 2: Treatment D
ORR Per RECISTS v1.1 by BICR in Part 250.6 (43.8 to 57.4)43.0 (36.2 to 50.1)
Statistical analysis
  • Part 2: Treatment C vs Part 2: Treatment D · Cochran-Mantel-Haenszel · Odds ratio (or): 1.39 · 90% CI 0.94 to 2.05
SecondaryTRAEs Leading to Discontinuation in Part 1

Number of participants with treatment related adverse events (TRAEs) leading to discontinuation based on grade. AE is defined as any new untoward medical occurrence or worsenig of a preexising medical condition in a clinical investigation participant administered study treatment and that does not necessarily have a causal relationship with this treatment. Grading will be determined for severity according to the NCI CTCAE v5.0

Time frame:
From first dose to 30 days post last dose of study therapy (Approximately 32.8 Months)
Reported as:
Count of participants · Participants
TRAEs Leading to Discontinuation in Part 1
ParticipantsPart 1: Treatment APart 1: Treatment B
Any Grade2118
Grade 3 to 41312
Grade 510
SecondaryNumber of Participants With a Treatment Related AEs in Part 1

Number of participants with a treatment related AE in part 1. AE is defined as any new untoward medical occurrence or worsenig of a preexising medical condition in a clinical investigation participant administered study treatment and that does not necessarily have a causal relationship with this treatment. Grading will be determined for severity according to the NCI CTCAE v5.0

Time frame:
From first dose to 30 days post last dose of study therapy (Approximately 32.8 Months)
Reported as:
Count of participants · Participants
Number of Participants With a Treatment Related AEs in Part 1
ParticipantsPart 1: Treatment APart 1: Treatment B
Number of Participants With a Treatment Related AEs in Part 17576
SecondaryNumber of Participants With Treatment Releted SAEs in Part 1

A serious adverse event (SAE) is defined as any untoward medical occurrence that at any dose, results in death, is life-threatening, requires inpatient hospitalization or causes prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, or is an important medical event (defined as a medical event(s) that may not be immediately life-threatening or result in death or hospitalization but, based upon appropriate medical and scientific judgment, may jeopardize the participant or may require intervention \[e.g., medical, surgical\] to prevent one of the other serious outcomes listed in the definition). Grading will be determined for severity according to the NCI CTCAE v5.0.

Time frame:
From first dose to 30 days post last dose of study therapy (Approximately 32.8 Months)
Reported as:
Count of participants · Participants
Number of Participants With Treatment Releted SAEs in Part 1
ParticipantsPart 1: Treatment APart 1: Treatment B
Any Grade2024
Grade 3 to 41418
Grade 524
SecondaryNumber of Participants With Treatment Releted Select AEs in Part 1

AE is defined as any new untoward medical occurrence or worsenig of a preexising medical condition in a clinical investigation participant administered study treatment and that does not necessarily have a causal relationship with this treatment. Select Adverse Events (AEs) will be determined for severity according to the NCI CTCAE v5.0.

Time frame:
From first dose to 30 days post last dose of study therapy (Approximately 32.8 Months)
Reported as:
Count of participants · Participants
Number of Participants With Treatment Releted Select AEs in Part 1
ParticipantsPart 1: Treatment APart 1: Treatment B
Gastrointestinal1815
Hepatic2618
Pulmonary45
Renal94
Skin2418
Hypersensitivity/Infusion Reaction52
SecondaryORR by PD-L1 Expression Per RECISTS v1.1 by BICR in Part 2

Objective Response Rate (ORR) per RECIST v1.1 by BICR is defined as the number of participants in the randomized population who achieve a best overall response (BOR) of confirmed complete response (CR) or confirmed partial response (PR) based on BICR assessments (using RECIST v1.1) divided by the number of participants in the population. BOR is defined as the best response, as determined by the BICR, recorded between the date of randomization and the date of first objectively documented progression per RECIST v1.1 or the date of subsequent therapy, whichever occurs first.

Time frame:
Approximately 14.8 Months
Reported as:
Number · Percentage of Participants
ORR by PD-L1 Expression Per RECISTS v1.1 by BICR in Part 2
Percentage of ParticipantsPart 2: Treatment CPart 2: Treatment D
PD-L1 <1%48.6 (38.2 to 59.0)44.8 (34.4 to 55.5)
PD-L1 >= 1%53.2 (43.3 to 62.8)39.4 (29.7 to 49.9)
Not Quantifiable44.4 (16.9 to 74.9)53.8 (28.7 to 77.6)
SecondaryDoR Per RECISTS v1.1 by BICR in Part 2

Duration of Response (DOR) will be assessed by BICR. It is defined as the time between the date of first documented response (CR or PR) that is subsequently confirmed, to the date of the first objectively documented tumor progression as determined by the BICR (per RECIST v1.1), or death due to any cause, whichever occurs first.

Time frame:
Approximately up to 13.7 months
Reported as:
Median · Months
DoR Per RECISTS v1.1 by BICR in Part 2
MonthsPart 2: Treatment CPart 2: Treatment D
DoR Per RECISTS v1.1 by BICR in Part 28.41 (7.43 to NA)7.10 (5.62 to NA)
SecondaryNumber of Participants With a AE in Part 2

Number of participants with an adverse event (AE). AE is defined as any new untoward medical occurrence or worsenig of a preexising medical condition in a clinical investigation participant administered study treatment and that does not necessarily have a causal relationship with this treatment. Grading will be determined for severity according to the NCI CTCAE v5.0.

Time frame:
From first dose to 30 days post last dose of study therapy (Approximately 14.8 Months)
Reported as:
Count of participants · Participants
Number of Participants With a AE in Part 2
ParticipantsPart 2: Treatment CPart 2: Treatment D
Any Grade158147
Grade 3 to 49085
Grade 52619
SecondaryNumber of Participants With a Treatment Related AEs in Part 2

AE is defined as any new untoward medical occurrence or worsenig of a preexising medical condition in a clinical investigation participant administered study treatment and that does not necessarily have a causal relationship with this treatment. Grading will be determined for severity according to the NCI CTCAE v5.0.

Time frame:
From first dose to 30 days post last dose of study therapy (Approximately 14.8 Months)
Reported as:
Count of participants · Participants
Number of Participants With a Treatment Related AEs in Part 2
ParticipantsPart 2: Treatment CPart 2: Treatment D
Any Grade147138
Grade 3 to 47978
Grade 544
SecondaryNumber of Participants With a Treatment Related SAEs in Part 2

SAE is defined as a life-threatening (defined as an event in which the participant was at risk of death at the time of the event; it does not refer to an event which hypothetically might have caused death if it were more severe). SAEs can also result in death. The AE requires inpatient hospitalization or causes prolongation of existing hospitalization. Results in persistent or significant disability/incapacity. Is a congenital anomaly/birth defect. Is an important medical event (defined as a medical event(s) that may not be immediately lifethreatening or result in death or hospitalization but, based upon appropriate medical and scientific judgment, may jeopardize the participant or may require intervention \[e.g., medical, surgical\] to prevent one of the other serious outcomes listed in the definition above.) Grading will be determined for severity according to the NCI CTCAE v5.0.

Time frame:
From first dose to 30 days post last dose of study therapy (Approximately 14.8 Months)
Reported as:
Count of participants · Participants
Number of Participants With a Treatment Related SAEs in Part 2
ParticipantsPart 2: Treatment CPart 2: Treatment D
Any Grade3436
Grade 3 to 42628
Grade 544
SecondaryNumber of Participants With Endocrine Immune-mediated Adverse Events in Part 2

IMAEs are AEs consistent with an immune-mediated mechanism or immune-mediated component for which non-inflammatory etiologies (eg, infection or tumor progression) have been ruled out. IMAEs can include events with an alternate etiology which were exacerbated by the induction of autoimmunity. Grading will be determined for severity according to the NCI CTCAE v5.0.

Time frame:
From first dose to 30 days post last dose of study therapy (Approximately 14.8 Months)
Reported as:
Count of participants · Participants
Number of Participants With Endocrine Immune-mediated Adverse Events in Part 2
ParticipantsPart 2: Treatment CPart 2: Treatment D
Adrenal Insufficiency23
Hypothyroidism/Thyroiditis2213
Hypothyroidism2113
Thyroiditis20
Diabetes Mellitus10
Hyperthyroidism143
Hypophysitis01
SecondaryORR by LAG-3 Expression Per RECISTS v1.1 by BICR in Part 2

Objective Response Rate (ORR) per RECIST v1.1 by BICR is defined as the number of participants in the randomized population who achieve a best overall response (BOR) of confirmed complete response (CR) or confirmed partial response (PR) based on BICR assessments (using RECIST v1.1) divided by the number of participants in the population. BOR is defined as the best response, as determined by the BICR, recorded between the date of randomization and the date of first objectively documented progression per RECIST v1.1 or the date of subsequent therapy, whichever occurs first.

Time frame:
On Going

Results for this outcome have not been posted.

SecondaryORR by FG-L1 Expression Per RECISTS v1.1 by BICR in Part 2

Objective Response Rate (ORR) per RECIST v1.1 by BICR is defined as the number of participants in the randomized population who achieve a best overall response (BOR) of confirmed complete response (CR) or confirmed partial response (PR) based on BICR assessments (using RECIST v1.1) divided by the number of participants in the population. BOR is defined as the best response, as determined by the BICR, recorded between the date of randomization and the date of first objectively documented progression per RECIST v1.1 or the date of subsequent therapy, whichever occurs first.

Time frame:
Ongoing

Results for this outcome have not been posted.

SecondaryPFS Per RECISTS v1.1 by BICR in Part 2

Progression Free Survival is defined as the time between the date of randomization and the first date of documented progression, based on BICR assessments (per RECIST v1.1), or death due to any cause, whichever occurs first.

Time frame:
Ongoing

Results for this outcome have not been posted.

SecondaryPFS by PD-L1 Expression Per RECISTS v1.1 by BICR in Part 2

Progression Free Survival is defined as the time between the date of randomization and the first date of documented progression, based on BICR assessments (per RECIST v1.1), or death due to any cause, whichever occurs first.

Time frame:
Ongoing

Results for this outcome have not been posted.

SecondaryPFS by LAG-3 Expression Per RECISTS v1.1 by BICR in Part 2

Progression Free Survival is defined as the time between the date of randomization and the first date of documented progression, based on BICR assessments (per RECIST v1.1), or death due to any cause, whichever occurs first.

Time frame:
Ongoing

Results for this outcome have not been posted.

SecondaryPFS by FG-L1 Expression Per RECISTS v1.1 by BICR in Part 2

Progression Free Survival is defined as the time between the date of randomization and the first date of documented progression, based on BICR assessments (per RECIST v1.1), or death due to any cause, whichever occurs first.

Time frame:
Ongoing

Results for this outcome have not been posted.

SecondaryNumber of Participants With Treatment Releted Select AEs in Part 2

AE is defined as any new untoward medical occurrence or worsenig of a preexising medical condition in a clinical investigation participant administered study treatment and that does not necessarily have a causal relationship with this treatment. Select Adverse Events (AEs) will be determined for severity according to the NCI CTCAE v5.0.

Time frame:
Ongoing

Results for this outcome have not been posted.

Adverse events

Collected over All-Cause mortality, Adverse Events and Serious Adverse Events: (From first dose to last dose + 135 days): Approximately 36 Months. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Part 1: Treatment A47/77 (61%)46/77 (59.7%)74/77 (96.1%)
Part 1: Treatment B46/79 (58.2%)52/79 (65.8%)78/79 (98.7%)
Part 2: Treatment C79/158 (50%)103/158 (65.2%)151/158 (95.6%)
Part 2: Treatment D70/149 (47%)81/149 (54.4%)145/149 (97.3%)
Most frequent serious events
Showing 10 of 184
Most frequent serious events
EventPart 1: Treatment APart 1: Treatment BPart 2: Treatment CPart 2: Treatment D
Malignant neoplasm progressionNeoplasms benign, malignant and unspecified (incl cysts and polyps)7/778/7940/15836/149
Febrile neutropeniaBlood and lymphatic system disorders3/777/794/1587/149
PneumoniaInfections and infestations5/776/7914/15810/149
General physical health deteriorationGeneral disorders0/776/793/1582/149
NeutropeniaBlood and lymphatic system disorders1/773/794/15810/149
Pulmonary embolismRespiratory, thoracic and mediastinal disorders4/773/792/1581/149
Atrial fibrillationCardiac disorders0/774/792/1580/149
AnaemiaBlood and lymphatic system disorders3/772/796/1583/149
COVID-19Infections and infestations3/770/793/1580/149
SepsisInfections and infestations3/772/790/1584/149
Most frequent other events
Showing 10 of 100
Most frequent other events
EventPart 1: Treatment APart 1: Treatment BPart 2: Treatment CPart 2: Treatment D
AnaemiaBlood and lymphatic system disorders51/7743/79109/15892/149
NauseaGastrointestinal disorders33/7729/7955/15840/149
FatigueGeneral disorders33/7725/7943/15837/149
AstheniaGeneral disorders30/7727/7937/15836/149
ConstipationGastrointestinal disorders29/7717/7933/15820/149
NeutropeniaBlood and lymphatic system disorders28/7729/7938/15838/149
DiarrhoeaGastrointestinal disorders26/7718/7934/15830/149
Decreased appetiteMetabolism and nutrition disorders21/7724/7927/15834/149
ThrombocytopeniaBlood and lymphatic system disorders14/7716/7947/15834/149
DyspnoeaRespiratory, thoracic and mediastinal disorders20/7718/7915/15814/149

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Part 1: Treatment APart 1: Treatment BPart 2: Treatment CPart 2: Treatment DTotal
<=18 years00000
Between 18 and 65 years37427372224
>=65 years42388579244
Sex: Female, Male
Sex: Female, Male(Participants)Part 1: Treatment APart 1: Treatment BPart 2: Treatment CPart 2: Treatment DTotal
Female28325557172
Male514810394296
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Part 1: Treatment APart 1: Treatment BPart 2: Treatment CPart 2: Treatment DTotal
Hispanic or Latino1612312887
Not Hispanic or Latino37449188260
Unknown or Not Reported26243635121
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Part 1: Treatment APart 1: Treatment BPart 2: Treatment CPart 2: Treatment DTotal
American Indian or Alaska Native00000
Asian00011
Native Hawaiian or Other Pacific Islander00000
Black or African American10225
White7577148141441
More than one race00000
Unknown or Not Reported338721
08

Study locations

125 sites
  • Local Institution - 0160
    Duarte, California 91010, United States
  • Local Institution - 0081
    Orange, California 92868, United States
  • Local Institution - 0139
    New Haven, Connecticut 06520, United States
  • Local Institution - 0153
    Jacksonville, Florida 32204, United States
  • Local Institution - 0011
    Port Saint Lucie, Florida 34952, United States
  • Local Institution - 0089
    Athens, Georgia 30607, United States
  • Local Institution - 0121
    Wichita, Kansas 67214, United States
  • Local Institution - 0159
    Lexington, Kentucky 40503, United States
  • Local Institution - 0002
    Louisville, Kentucky 40241, United States
  • Local Institution - 0082
    Scarborough, Maine 04074, United States
  • Local Institution - 0129
    Omaha, Nebraska 68130, United States
  • Local Institution - 0152
    Howell Township, New Jersey 07731, United States
  • Local Institution - 0124
    Johnson City, New York 13790, United States
  • Local Institution - 0162
    Mineola, New York 11501, United States
  • Local Institution - 0128
    New York, New York 10016, United States
  • Local Institution - 0165
    New York, New York 10021, United States
  • Local Institution - 0097
    The Bronx, New York 10461, United States
  • Local Institution - 0117
    Durham, North Carolina 27710, United States
  • Local Institution - 0156
    Cincinnati, Ohio 45219, United States
  • Local Institution - 0155
    Cleveland, Ohio 44109, United States
  • Local Institution - 0084
    Lancaster, Pennsylvania 17604, United States
  • Local Institution - 0147
    Pittsburgh, Pennsylvania 15212, United States
  • Local Institution - 0148
    Providence, Rhode Island 02903, United States
  • Local Institution - 0083
    Greenville, South Carolina 29607, United States
  • Local Institution - 0149
    Dallas, Texas 75390-9179, United States
  • Local Institution - 0091
    Harlingen, Texas 78550, United States
  • Local Institution - 0001
    Tyler, Texas 75701, United States
  • Local Institution - 0092
    Spokane, Washington 99208, United States
  • Local Institution - 0157
    Morgantown, West Virginia 26506, United States
  • Local Institution - 0037
    Río Cuarto, Córdoba Province 5800, Argentina
  • Local Institution - 0021
    Buenos Aires, Distrito Federal C1426, Argentina
  • Local Institution - 0014
    Cuiudad Autonoma de Buenos Aires, Distrito Federal C1430EGF, Argentina
  • Local Institution - 0039
    Viedma, Río Negro Province 8500, Argentina
  • Local Institution - 0029
    Rosario, Santa Fe Province 2000, Argentina
  • Local Institution - 0060
    Córdoba, 5006, Argentina
  • Local Institution - 0038
    Córdoba, X5004FHP, Argentina
  • Local Institution - 0073
    La Rioja, F5300COE, Argentina
  • Local Institution - 0055
    Camperdown, New South Wales 2050, Australia
  • Local Institution - 0086
    Gosford, New South Wales 2250, Australia
  • Local Institution - 0132
    Tamworth, New South Wales 2340, Australia
  • Local Institution - 0057
    Adelaide, South Australia 5087, Australia
  • Local Institution - 0130
    Ballarat, Victoria 3350, Australia
  • Local Institution - 0138
    Bendigo, Victoria 3550, Australia
  • Local Institution - 0141
    Box Hill, Victoria 3128, Australia
  • Local Institution - 0109
    Frankston, Victoria 3199, Australia
  • Local Institution - 0119
    Murdoch, Western Australia 6150, Australia
  • Local Institution - 0085
    Nedlands, Western Australia 6009, Australia
  • Local Institution - 0090
    Graz, 8036, Austria
  • Local Institution - 0126
    Vienna, 1090, Austria
  • Local Institution - 0127
    Ghent, 9000, Belgium
  • Local Institution - 0131
    Ghent, 9000, Belgium
  • Local Institution - 0125
    Roeselare, 8800, Belgium
  • Local Institution - 0063
    Natal, Rio Grande do Norte 59062 000, Brazil
  • Local Institution - 0161
    Ijuí, Rio Grande do Sul 98700-000, Brazil
  • Local Institution - 0116
    Porto Alegre, Rio Grande do Sul 90050-170, Brazil
  • Local Institution - 0112
    Porto Alegre, Rio Grande do Sul 91350-200, Brazil
  • Local Institution - 0107
    Barretos, São Paulo 14784-400, Brazil
  • Local Institution - 0111
    Santo André, São Paulo 09060-870, Brazil
  • Local Institution - 0072
    Rio de Janeiro, 20220-410, Brazil
  • Local Institution - 0163
    São Paulo, 04014-002, Brazil
  • Local Institution - 0120
    São Paulo, 08270-120, Brazil
  • Local Institution - 0079
    Santiago, Santiago Metropolitan 0, Chile
  • Local Institution - 0041
    Santiago, Santiago Metropolitan 7500713, Chile
  • Local Institution - 0016
    Santiago, Santiago Metropolitan 7500921, Chile
  • Local Institution - 0008
    Rennes, Ille-Et-Vilaine 35000, France
  • Local Institution - 0007
    Dijon, 21 000, France
  • Local Institution - 0144
    Le Mans, 72037, France
  • Local Institution - 0102
    Paris, 75014, France
  • Local Institution - 0035
    Paris, 75018, France
  • Local Institution - 0006
    Saint-Mandé, 94160, France
  • Local Institution - 0110
    Paris, Île-de-France Region 75005, France
  • Local Institution - 0065
    Essen, North Rhine-Westphalia 45136, Germany
  • Local Institution - 0103
    Berlin, 12351, Germany
  • Local Institution - 0045
    Berlin, 13585, Germany
  • Local Institution - 0062
    Großhansdorf, 22927, Germany
  • Local Institution - 0058
    Homburg, 66421, Germany
  • Local Institution - 0108
    Löwenstein, 74245, Germany
  • Local Institution - 0071
    Marburg, 35043, Germany
  • Local Institution - 0050
    Paderborn, 33098, Germany
  • Local Institution - 0030
    Ravensburg, 88212, Germany
  • Local Institution - 0133
    Elm Park, Dublin 4, Ireland
  • Local Institution - 0023
    Dublin, 00009, Ireland
  • Local Institution - 0106
    Rome, RA 00144, Italy
  • Local Institution - 0028
    Candiolo, 10060, Italy
  • Local Institution - 0009
    Catania, 95125, Italy
  • Local Institution - 0032
    Genova, 16149, Italy
  • Local Institution - 0059
    Milan, 20141, Italy
  • Local Institution - 0164
    Pesaro, 61122, Italy
  • Local Institution - 0019
    Siena, 53100, Italy
  • Local Institution - 0070
    Mexico City, Mexico City 14050, Mexico
  • Local Institution - 0115
    Monterrey, Nuevo León 64710, Mexico
  • Local Institution - 0013
    San Pedro Garza García, Nuevo León 66220, Mexico
  • Local Institution - 0020
    Toluca, State of Mexico 50090, Mexico
  • Local Institution - 0053
    Harderwijk, Gelderland 3844, Netherlands
  • Local Institution - 0158
    Arnhem, 6815, Netherlands
  • Local Institution - 0145
    Gdynia, 81-519, Poland
  • Local Institution - 0036
    Lublin, 20-090, Poland
  • Local Institution - 0031
    Lublin, 20-093, Poland
  • Local Institution - 0080
    Olsztyn, 10-357, Poland
  • Local Institution - 0088
    Warsaw, 02-781, Poland

Showing the first 100 of 125 sites across 19 countries. Choose a country and city above to see the rest.

09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — BMS will provide access to individual anonymized participant data upon request from qualified researchers, and subject to certain criteria. Additional information regarding Bristol Myer Squibb's data sharing policy and process can be found at https://www.bms.com/researchers-and-partners/clinical-trials-and-research.html

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: See Plan Description

Access criteria: See Plan Description

Data sharing details ↗ · www.bms.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2021 to primary completion in Jan 2024, 34 months.

Results were first posted in Mar 2025, 1 year 2 months after primary completion.

Of 317 industry-sponsored phase 2 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 59. This study's 34 months is close to that.

Counting every sponsor, half of 1,046 studies reached it within 48 months; a quarter within 30 and three quarters within 76.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 5, 2020
First posted
Nov 10, 2020
StartActual
Feb 17, 2021
Primary completionActual
Jan 11, 2024
CompletionActual
May 6, 2026
Results first posted
Mar 18, 2025
Last update
Jun 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 18, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04623775
Responsible party
Sponsor
First posted
Nov 10, 2020
Start date
Feb 17, 2021
Primary completion
Jan 11, 2024
Completion
May 6, 2026
Results posted
Mar 18, 2025
Last update
Jun 18, 2026

Study contacts

Bristol-Myers Squibb
study director · Bristol-Myers Squibb

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Relatlimab

Start the discussion